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Skeletal muscle comprises approximately 40% of body weight, and is important for
locomotion, as well as for metabolic homeostasis. Adult skeletal muscle mass is
maintained by a fine balance between muscle protein synthesis and degradation. In
response to cytokines, nutrients, and mechanical stimuli, skeletal muscle mass is
increased (hypertrophy), whereas skeletal muscle mass is decreased (atrophy) in a
variety of conditions, including cancer cachexia, starvation, immobilization, aging, and
neuromuscular disorders. Recent studies have determined two important signaling
pathways involved in skeletal muscle mass. The insulin-like growth factor-1 (IGF-1)/Akt
pathway increases skeletal muscle mass via stimulation of protein synthesis and inhibition
of protein degradation. By contrast, myostatin signaling negatively regulates skeletal
muscle mass by reducing protein synthesis. In addition, the discovery of microRNAs
as novel regulators of gene expression has provided new insights into a multitude
of biological processes, especially in skeletal muscle physiology. We summarize here
the current knowledge of microRNAs in the regulation of skeletal muscle hypertrophy,
focusing on the IGF-1/Akt pathway and myostatin signaling.
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INTRODUCTION
Skeletal muscle is the most abundant tissue in our body and is
important in locomotion and metabolic adaptation. Adult skele-
tal muscle mass is mainly determined by a balance between
muscle protein synthesis and degradation. Exercise, nutrients,
and exogenous stimuli increase the rate of muscle protein syn-
thesis and increase skeletal muscle mass (hypertrophy), whereas
starvation, immobilization, aging, and diseases increase the rate
of protein degradation and markedly reduce skeletal muscle
mass (atrophy). In addition, some muscular disorders produce
a larger but much weaker muscle (pseudo-hypertrophy) through
degeneration and regeneration of myofibers (Tyler, 2003). Several
signaling pathways are shown to be involved in the regula-
tion of skeletal muscle mass. The insulin-like growth factor-1
(IGF-1)/Akt pathway and β-adrenergic pathway are positive regu-
lators of skeletal muscle growth. In contrast, myostatin signaling,
NF-κβ signaling, and glucocorticoid signaling negatively regulate
skeletal muscle mass (Sandri, 2008).
MicroRNAs (miRNAs) are small non-coding RNAs that are
highly conserved in eukaryotes. Currently, the important role
of miRNAs is evident in diverse biological processes, including
development, differentiation, homeostasis, and disease in verte-
brate species (Sayed and Abdellatif, 2011). miRNAs function to
fine tune gene expression by accelerating degradation of mRNA
and/or by inhibiting translation (Bartel, 2009). Identification
of muscle-specific miRNAs called myomiR (miR-1, miR-133a/b,
miR-206, miR-208b, miR-499, and miR-486) has extended our
knowledge of the molecular network in skeletal muscle. The
myomiRs form a feedback regulatory loop with myogenic reg-
ulatory factors, such as MyoD and myogenin, to precisely reg-
ulate skeletal muscle plasticity. For example, miR-1, mir-27,
miR-206, andmiR-486 promote myoblast differentiation through
the repression of Pax7 and Pax3 expression (Crist et al., 2009;
Chen et al., 2010; Dey et al., 2011). Meanwhile, the expression of
myomiRs is strictly controlled by MyoD, myogenin, MEF2, and
Pax7 (Rao et al., 2006; Rosenberg et al., 2006; Liu et al., 2007; Dey
et al., 2011).
This mini-review highlights the recent findings of miRNAs in
skeletal muscle hypertrophy, and focuses on the IGF-1/Akt path-
way and myostatin signaling, because the fine balance between
these two signaling pathways is essential for maintaining normal
skeletal muscle mass (Schiaffino et al., 2013). The role of miRNAs
on the IGF-1/Akt pathway andmyostatin signaling is summarized
in Figure 1. miRNAs also function in skeletal muscle atrophy and
their role has been described in detail in recent reviews (Ma et al.,
2012; Wang, 2013).
THE IGF-1/AKT PATHWAY AND microRNAs
IGF-1 binds to its own tyrosine kinase receptor IGF-1R
and activates phosphatidylinositol-3-kinase (PI3K) through
IRS1. Activated PI3K produces phosphatidylinositol-
3,4,5,triphosphates (PIP3) and then induces activation of
the Akt protein. Subsequently, Akt activates mammalian target
of rapamycin (mTOR) and regulates down stream effector p70
ribosomal protein S6 kinase (p70S6K) and 4E-BP1, both of
which control protein synthesis (Rommel et al., 2001). Akt
also inactivates glycogen synthase kinase 3β (GSK3β), which
blocks protein translation (Cross et al., 1995). In addition, Akt
inhibits the nuclear translocation of FoxO family of transcription
factors. Because FoxOs play a key role in the regulation of muscle
atrophy-related genes, MuRF1, and Atrogin1 (Sandri et al., 2004),
inactivation of FoxOs prevents muscle protein degradation. In
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FIGURE 1 | Schematic representation of miRNAs involved in the
regulation of the IGF-1/Akt pathway and myostatin signaling. IGF-1
increases the activity of Akt protein. This activation of Akt is attenuated by
PTEN. The activated state of Akt stimulates protein synthesis through mTOR.
Akt also inhibits protein degradation by suppressing the activity of GSK3β and
FoxO1, which induces protein degradation by activating the expression of
MuRF1 and Atrogin1. Therefore, the IGF-1/Akt pathway induces skeletal
muscle hypertrophy. Recent studies have shown that miR-1, miR-133,
miR-206, and miR-128a negatively regulate the IGF-1/Akt pathway by
targeting positive regulators of the IGF-1/Akt pathway (IGF-1, IGF-1R, IRS1,
HSP70, or p70S6K), while miR-29, miR-486, and miR-23a positively regulate
this pathway by targeting negative regulators (PTEN, FoxO1, MuRF1, or
Atrogin1). In contrast to the IGF-1/Akt pathway, myostatin signaling is a
negative regulator of skeletal muscle mass. Myostatin activates Smad3
protein and may inhibit protein synthesis by repressing the transcription of
miR-486 and miR-29, which target PTEN and FoxO1 proteins. Conversely,
myostatin expression is regulated by miR-27a/b, miR-208a/b, and miR-499.
Red lines indicate the inhibitory function of miRNAs identified in skeletal
muscle, while red-dashed lines represent the inhibitory function of miRNAs
identified in cardiac muscle and cultured cells.
this manner, the IGF-1/Akt pathway plays a central role in skeletal
muscle hypertrophy. Indeed, ectopic Akt expression is sufficient
for increasing the size of myofibers in adult mice (Bodine et al.,
2001; Takahashi et al., 2002; Lai et al., 2004). Although the
effect of IGF-1 on skeletal muscle mass mainly depends on
development, IGF-1 can lead to increase skeletal muscle mass
even in adulthood (Adams and McCue, 1998; Barton-Davis et al.,
1998; Alzghoul et al., 2004; Schertzer et al., 2006).
Recent studies have identified several miRNAs that can modu-
late the muscle IGF-1/Akt pathway. In this section, we review the
recently discovered miRNAs that target the IGF-1/Atk pathway in
skeletal muscle.
MicroRNA-1, -133, AND -206
The expression levels of miR-1 and miR-133 are greatly increased
during myogenesis (Ge and Chen, 2011), whereas the levels of
their expression are reduced during skeletal muscle hypertrophy.
Functional overload in mice decreases the levels of miR-1 and
miR-133 expression with an increase in muscle weight (McCarthy
and Esser, 2007). Resistance training with amino acid ingestion
also decreases miR-1 expression in young men (Drummond
et al., 2008). Overload and acute resistance exercise are shown
to increase the levels of IGF-1 peptide in rats (Adams et al.,
1999) and the activity of the Akt/mTOR in humans, respectively
(Mayhew et al., 2009). Therefore, reduced miR-1 and miR-133
expression could contribute to the activation of the IGF-1/Akt
pathway. Indeed, miR-1 and miR-133 inhibit the IGF-1/Akt path-
way in C2C12 cells by targeting IGF-1, IGF-1R, and HSP70 (Elia
et al., 2009; Huang et al., 2011; Kukreti et al., 2013), however, their
targets in adult skeletal muscle remain to be defined.
Notably, inhibition of miR-206 in tilapia skeletal muscle pro-
motes body growth with an increase in IGF-1 expression (Yan
et al., 2013). However, although inhibition of miR-206 robustly
increases C2C12 myotube width, gain and loss of function of
miR-206 do not affect skeletal muscle size in vivo (Winbanks et al.,
2013).
MicroRNA-128a
To the best of our knowledge, miR-128a is the only miRNA
that has the potential to increase skeletal muscle mass. In mice,
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miR-128a is highly expressed in brain and skeletal muscle (Lee
et al., 2008), and its expression is increased during myoblast dif-
ferentiation (Chen et al., 2006, 2010; Sun et al., 2010). Motohashi
et al. (2013) identified IRS1 as a target of miR-128a in mice.
They showed that overexpression of miR-128a repressed myoblast
proliferation with a decrease in IRS1 protein and Akt activity.
Interestingly, inhibition of miR-128a increased the size of C2C12
myotubes, with an increase in IRS1 protein and Akt activity.
Notably, 4 weeks’ administration of antisense miR-128 signifi-
cantly induced skeletal muscle hypertrophy in mice. Given that
miR-128 inhibits glioma tumor growth by targeting p70S6K (Shi
et al., 2012), miR-128a may act as a negative regulator against
multiple components of the IGF-1/Akt anabolic pathway.
MicroRNA-486
An alternative promoter, located upstream of exon 39a of the
Ank1 gene, produces cardiac and skeletal muscle-specific Ank1.5
protein (also referred to as sAnk1), which connects sarcomeres to
the sarcoplasmic reticulum (Zhou et al., 1997; Porter et al., 2005).
miR-486 is transcribed from the final intron of the Ank1.5 gene,
and is co-expressed with Ank1.5 mRNA in cardiac and skeletal
muscles (Small et al., 2010).
miR-486 was initially identified as a downstream target
of myocardin-related transcription factor-A in cardiomyocytes
(Small et al., 2010). MyoD also directly stimulates the promoter
activity of miR-486/Ank1.5 and increases their expression during
myoblast differentiation (Dey et al., 2011). miR-486 promotes the
differentiation of satellite cells, adult skeletal muscle stem cells,
by targeting Pax7 mRNA (Dey et al., 2011), whereas muscle-
specific transgenic overexpression of miR-486 shows delayed
regeneration when skeletal muscle is injured (Alexander et al.,
2011).
In addition, miR-486 is involved in the regulation of Akt activ-
ity by directly targeting the 3′ UTR of phosphatase and tensin
homolog (PTEN) and FoxO1. Because PTEN inactivates the Akt
protein (Stambolic et al., 1998), miR-486 increases the phospho-
rylation status of Akt with a decrease in PTEN and FoxO1 protein
levels in mouse primary myotubes (Xu et al., 2012). miR-486
also decreases protein levels of PTEN, FoxO1, PDGFRβ, SFSR1,
and SFSR3 in human myoblasts and myotubes (Alexander et al.,
2011). We recently showed that miR-486 is necessary to main-
tain Akt activity in C2C12 myotubes. Furthermore, inhibition of
miR-486 activity in vivo induced myofiber atrophy (Hitachi et al.,
2014). Interestingly, ectopic miR-486 expression blocked the sup-
pression of Akt activity caused by chronic kidney disease (CKD)
and was sufficient for preventing skeletal muscle atrophy induced
by CKD in mice (Xu et al., 2012). Therefore, miR-486 contributes
to maintain skeletal muscle mass through the regulation of Akt
activity.
MYOSTATIN SIGNALING AND microRNAs
Myostatin is a cytokine belonging to the transforming growth
factor-β (TGF-β) superfamily. In contrast to the IGF-1/Akt path-
way, myostatin signaling acts as a negative regulator of skeletal
muscle mass. The importance of myostatin in skeletal muscle
mass was first shown by McPherron et al. (1997). They generated
mice with deletion of the myostatin gene, which resulted in
doubled skeletal muscle weight due to an increase in muscle fiber
size (hypertrophy) and increased muscle fiber number (hyperpla-
sia). This groundbreaking research led to better understanding
of the mechanism for excessive skeletal muscle growth observed
in cattle, sheep, and dogs, which have naturally occurring muta-
tions in the myostatin gene (Grobet et al., 1997; McPherron and
Lee, 1997; Clop et al., 2006; Mosher et al., 2007). Importantly,
a naturally occurring mutation in the myostatin gene was found
in human with increased skeletal muscle mass (Schuelke et al.,
2004). The importance of myostatin in muscle size was further
supported by the finding that systemically administrated myo-
statin induces skeletal muscle atrophy in mice (Zimmers et al.,
2002). Notably elevated myostatin expression is correlated with
muscle wasting in cancer cachexia, heart failure, HIV, CKD,
chronic obstructive pulmonary disease, and aging (Gonzalez-
Cadavid et al., 1998; Yarasheski et al., 2002; Shyu et al., 2006;
Costelli et al., 2008; Plant et al., 2010; Verzola et al., 2011).
Currently, blockade of myostatin function is believed to be a
promising therapy against muscle wasting caused by neuromus-
cular disorders, cancer, and aging (Han et al., 2013).
Myostatin signaling is transmitted intracellularly through ser-
ine/threonine kinase receptors, including activin receptor type
IIB (ActRIIB) and activin receptor-like kinases (ALK4 or ALK5)
(Rebbapragada et al., 2003). After binding of myostatin to its
receptors, ALK4/ALK5 activates Smad2 and Smad3 by phos-
phorylation of the C-terminal domain (Langley et al., 2002;
Rebbapragada et al., 2003). Phosphorylated Smad2/3 can form
a complex together with Smad4, and it then moves to the
nucleus to mediate transcriptional regulation of target genes.
In early studies, satellite cells were once considered to be a
major source of myostatin deficiency-induced muscular hyper-
trophy because myostatin inhibits satellite cell activation and self-
renewal (McCroskery et al., 2003). Subsequently, several groups
have shown a direct effect of myostatin on myofibrillar protein
synthesis (Taylor et al., 2001; Welle et al., 2006, 2009, 2011).
Recent studies have shown that satellite cells minimally con-
tribute to skeletal muscle hypertrophy by inhibition of myostatin
(Amthor et al., 2009; Lee et al., 2012; Wang and McPherron,
2012).
In 2006, a relationship betweenmyostatin andmiRNAwas first
shown in sheep. Clop et al. found a G to C single nucleotide poly-
morphism in the 3′ UTR of the myostatin gene in Texel sheep,
which show remarkable skeletal muscle hypertrophy (Clop et al.,
2006). This single nucleotide polymorphism changes the 3′ UTR
of myostatin into the target of miR-206. Accordingly, the expres-
sion level of myostatin is low in Texel sheep. After this discovery,
several miRNAs have been shown to be involved in myostatin sig-
naling. In this section, we summarize the current knowledge of
miRNAs related to myostatin signaling.
MicroRNA-27
miR-27 consists of miR-27a and miR-27b, which differ by one
nucleotide at position 19. During mice embryogenesis, miR-27b
is expressed in the limb bud, tail bud, neural tube, heart, and
somites (Crist et al., 2009). miR-27b expression is also upregu-
lated during satellite cell differentiation in adult mice (Crist et al.,
2009). Gain and loss of function of miR-27b initially indicated
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that miR-27b promotes myogenic differentiation by downregu-
lating Pax3 expression (Crist et al., 2009). Consistent with this
finding, miR-27b and Pax3 mRNA are exclusively expressed in
somites. miR-27b is expressed in myotomes and sclerotomes,
while Pax3 mRNA is expressed in dermomyotomes (Crist et al.,
2009).
Skeletal muscle mainly consists of three types of fibers, which
are slow oxidative, fast oxidative glycolytic, and fast glycolytic
fibers. Myostatin mRNA is highly expressed in fast-twitch mus-
cle, while its expression is low in slow-twitch muscle (Allen et al.,
2008). Surprisingly, the expression level of myostatin pre-mRNA
is indistinguishable between these two types of muscle. Allen and
Loh resolved this paradox to discover post-transcriptional con-
trol of myostatin mRNA by miR-27. They showed that miR-27a/b
is highly expressed in slow-twitch muscle and reduced the stabil-
ity ofmyostatinmRNA by direct binding to the 3′ UTR (Allen and
Loh, 2011). Therefore, lowmyostatin levels in slow-twitch muscle
are maintained by miR-27 in a post-transcriptional mechanism.
In mouse embryos at day 10.5, myostatin mRNA is expressed in
the myotome compartment (McPherron et al., 1997) where miR-
27b is expressed (Crist et al., 2009). Accordingly, the regulatory
mechanism of myostatin mRNA may differ between adult and
embryonic muscle.
Piedmontese cattle show the double-muscled phenotype,
which is inherited, and is caused by a point mutation in the myo-
statin gene. Missense mutation of the myostatin gene G938A is
translated to C313Y, and this alters the activity of myostatin pro-
tein (Berry et al., 2002), and induces muscle hypertrophy and
hyperplasia (Kambadur et al., 1997; McPherron and Lee, 1997).
Although 96% of Piedmontese cattle have a homozygosis muta-
tion of the myostatin gene, different phenotypes of muscularity
are observed in this breed. Greatly increased miR-27b expres-
sion with a decrease in myostatin expression have been found in
Piedmontese cattle (Miretti et al., 2013). However, the cause of
differential expression of miR-27b in this breed is unclear.
In humans, ingestion of leucine-enriched essential amino acids
quickly stimulates muscle protein synthesis (Fujita et al., 2007)
with a decrease in myostatin mRNA expression (Drummond
et al., 2009). Expression levels of miR-27 have not yet been
determined in this situation. However, considering the fact that
treatment of 1mM leucine decreases myostatin expression with
an increase in miR-27a expression in C2C12 cells (Chen et al.,
2013), miR-27 might contribute to reduce myostatin expression
even in human skeletal muscle.
MicroRNA-208a, -208b, AND -499
Three related myomiRs, miR-208a, miR-208b, and miR-499, are
encoded by introns of the myosin genes (miR-208a/Myh6, miR-
208b/Myh7, and miR-499/Myh7b). Expression of miR-208a is
heart specific, while miR-208b and miR-499 are expressed in car-
diac and slow-twitch skeletal muscle (van Rooij et al., 2009). In
skeletal muscle, miR-208b and miR-499 promote the formation
of slow-twitch fibers, because these miRNAs increase the expres-
sion of slowmuscle genes by repressing Sox6, Pur-β, and Sp3 (van
Rooij et al., 2009). Accordingly, double knockout of miR-208b
and miR-499 in mice leads to a loss of slow fibers in the soleus
(van Rooij et al., 2009).
Recent studies have shown the direct association of miR-
208a, miR-208b, and miR-499 with the 3′ UTR of myostatin by
luciferase assays (Callis et al., 2009; Bell et al., 2010). Although
miR-208a induces cardiac hypertrophy with decreased myostatin
expression (Callis et al., 2009), whether miR-208b and miR-499
have potential to induce skeletal muscle hypertrophy has not
been described. It is noteworthy that nutrient ingestion increases
miR-208b and miR-499 expressions with a decrease in myostatin
expression in human vastus lateralis muscle (Drummond et al.,
2009). Therefore, future studies are required to determine the
function of miR-208b and miR-499 in the regulation of skeletal
muscle mass.
MicroRNAs UNDER THE CONTROL OF MYOSTATIN SIGNALING
Thus far, we have described miRNAs that affect myostatin expres-
sion. Various studies have also investigated the opposite situation
of whether myostatin-related signaling alters the expression of
miRNAs. Davis et al. (2008) found that, in response to TGF-β and
BMP, Smad proteins (Smad3 and Smad1/5) accelerated the pro-
cessing ofmiR-21 in human smoothmuscle cells. In this situation,
Smad proteins interacted with RNA helicase p68, a component of
the Drosha complex. Smad proteins were later shown to directly
bind to the RNA-Smad binding element of primary transcripts of
miRNAs and facilitate the interaction between miRNAs and the
Drosha complex (Davis et al., 2010). BMP-2 is also likely to reg-
ulate the biogenesis of miR-206 using Smad proteins in C2C12
cells (Sato et al., 2009). Although altered expression of miR-1,
miR-133a/b, and miR-206 is found in myostatin knockout mice
(Rachagani et al., 2010), there is still no evidence that myostatin
directly regulates miRNA processing.
miR-29 was initially shown to accelerate muscle differenti-
ation by suppressing YY1 (Wang et al., 2008) and Akt3 (Wei
et al., 2013). miR-29 also attenuates the inhibitory effect of TGF-β
in muscle differentiation, and its expression is under regula-
tion of TGF-β and Smad3 (Winbanks et al., 2011; Zhou et al.,
2012). Interestingly, miR-29 activates the Akt pathway by target-
ing PTEN in cultured cells (Kong et al., 2011; Tumaneng et al.,
2012). Goodman et al. (2013) recently showed that in vivo trans-
fection of Smad3 reduced the Akt/mTOR activity and induced
myofiber atrophy. In this situation, increased PTEN mRNA trans-
lation with a decrease in miR-29 promoter activity was observed.
However, whether myostatin is involved in the regulation of miR-
29 expression and the function of miR-29 in the regulation of
skeletal muscle mass remain to be elucidated.
Most recently, we found greatly increased miR-486 expression
in myostatin knockout mice. We showed that myostatin signaling
repressed miR-486 expression at the transcriptional level using
Smad3 protein (Hitachi et al., 2014). As described above, miR-486
increases the Akt activity by targeting PTEN, therefore, several
miRNAs including miR-486 would contribute to induce skeletal
muscle hypertrophy from inhibition of myostatin by activating
the Akt pathway.
CONCLUSION
Although miRNAs have been implicated in skeletal muscle devel-
opment, regeneration, and function, our understanding of the
molecular mechanisms underlying the regulation of skeletal
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muscle mass by miRNAs is still limited. Exercise, nutrition, and
disease affect skeletal muscle mass postnatally, and they were
also recently shown to alter the levels of skeletal muscle miRNA
expression (Pasiakos and McClung, 2013; Zacharewicz et al.,
2013). Therefore, to understand the exact role of miRNAs in
skeletal muscle hypertrophy and atrophy, it is necessary to specif-
ically investigate the molecular function of miRNAs in adult
skeletal muscle without affecting development of skeletal mus-
cle. Indeed, using electric pulse-mediated gene transfer in adult
mice, Wada et al. (2011) clearly showed that ectopic expression of
miR-23a was sufficient to prevent dexamethasone-induced skele-
tal muscle atrophy. Future studies using in vivo techniques, such
as conditional transgenic and knockout technology, viral and
electrophoretic transfer of DNA and RNA, or tail vein injection
of nucleic acids with a modified backbone, will further define the
exact role of miRNAs in the regulation of skeletal muscle mass.
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